Abstracts tagged "Infection"

Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Ananta Subedi¹, Hong Fang² and Michelle Petri², ¹Good Samaritan Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1370 • 2013 ACR/ARHP Annual Meeting
Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases
Wieneke van den Hombergh¹, Annelies van Ede², J. Fransen³, Femke BG lamers-Karnebeek³, Saskia Kuipers⁴ and Matthijs Janssen⁵, ¹Rheumatology, UMC st. Radboud, Nijmegen, Netherlands, ²Rheumatology, UMC st Radboud, Nijmegen, Netherlands, ³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Microbiology, UMC st Radboud, Nijmegen, Netherlands, ⁵Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands
Background/Purpose: Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromized hosts. Prednisone is frequently suggested as a risk factor for developing pneumocystis pneumonia (PCP) in patients with rheumatic diseases. If prednisone…
Abstract Number: 1276 • 2013 ACR/ARHP Annual Meeting
Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab
Alysha Taxter¹, Kathleen E. Sullivan² and Jon Burnham³, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an anti-CD20 monoclonal antibody increasingly used in immunologic and malignant conditions to deplete B cells. Suppression of humoral immunity after rituximab exposure may…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting
The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Lucía Silva-Fernández^1,2, Mark Lunt³, Audrey S. Low², Kath D. Watson³, BSRBR Control Centre Consortium², Deborah P. Symmons², Kimme L. Hyrich⁴ and On behalf of the BSRBR⁵, ¹Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁵British Society for Rheumatology, London, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
Abstract Number: 730 • 2013 ACR/ARHP Annual Meeting
Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis
John McKinnon¹, Robbie Mailliard², Dawn McClemens-McBride³, Donald Jones³, Charles Rinaldo Jr.⁴ and Kathleen Maksimowicz-McKinnon⁵, ¹Infectious Disease, Henry Ford Hospital, Detroit, MI, ²Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA). The effects of GPA disease and…
Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting
Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Olivier Decaux⁷, Hélène Desmurs-Clavel⁸, Pierre Gobert⁹, Thomas Quemeneur¹⁰, Claire Blanchard-Delaunay¹¹, Pascal Godmer¹², Xavier Puechal¹³, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Francois Maurier¹⁸, Thomas Papo¹⁹, Matthias Büchler²⁰, Bernard Bonnotte²¹, Philippe Ravaud²² and Luc Mouthon²³, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Internal Medicine, Hôpital Cochin, PARIS, France, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁸University of Lyon, LYON, France, ⁹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹⁰Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹¹Internal Medicine, Hôpital de Niort, Niort, France, ¹²Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁹Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ²⁰Nephrology, University Hospital of Tours, TOURS, France, ²¹Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting
Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents
Jeffrey R. Curtis¹, Shuo Yang², Nivedita M. Patkar³, Lang Chen⁴, Jasvinder A. Singh⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷, Elizabeth S. Delzell⁸, Kenneth G. Saag⁹, Monika M. Safford¹⁰, Scott DuVall¹¹, Kimberly Alexander¹², Pavel Napalkov¹², Aaron Kamauu¹³ and John Baddley¹⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ¹⁰Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹¹VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ¹²Epidemiology, Genentech, Inc., South San Francisco, CA, ¹³Anolinx, Bountiful, UT, ¹⁴Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
Abstract Number: 2452 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation
Yaya Wang¹, Stephanie Stanford², Wenbo Zhou³, Jennifer L. Auger⁴, Genhong Cheng⁵, Amanda Campbell⁶, Fernanda M. Shoyama¹, Henry H. Balfour Jr.⁷, Andrew C. Chan⁸, Bryce A. Binstadt⁴, Nunzio Bottini⁶ and Erik J. Peterson³, ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³University of Minnesota, Minneapolis, MN, ⁴Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ⁵University of California, Los Angeles, Los Angeles, CA, ⁶La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁷University of Minnesota, Minneapolis, ⁸Immunology, Genentech Inc, South San Francisco, CA
Background/Purpose: A coding polymorphism (C1858T) in PTPN22 is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN22 encodes Lymphoid Phosphatase (Lyp);…
Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Pierre Charles¹, Antoine Néel², Nathalie Tieulié³, Arnaud Hot⁴, Grégory Pugnet⁵, Olivier Decaux⁶, Isabelle Marie⁷, Mehdi Khellaf⁸, Jean-Emmanuel Kahn⁹, Alexandre Karras¹⁰, Jean-Marc Ziza¹¹, Christophe Deligny¹², Colas Tchérakian¹³ and Loic Guillevin¹⁴, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Internal Medicine, Nantes University Hospital, Nantes, France, ³CHU Nice, Nice, France, ⁴Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁵Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁶Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁷Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁸Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ⁹Internal Medicine, Foch Hospital, Suresnes, France, ¹⁰Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ¹¹Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹³Service de pneumologie, hôpital Foch, Suresnes, France, ¹⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].